The U.S. Food and Drug Administration (FDA) has granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib. This means the drug will be available for early access to those who previously received conventional treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). A health care provider must request access to the medication for their patient, according to an FDA statement.
This article was originally published on MedicalXpress.com
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
© 2025 SimplyWell.ca